Tango Therapeutics released positive phase I/II data for vopimetostat (TNG‑462), a next‑generation PRMT5 inhibitor that leverages MTAP deletion cooperativity, showing encouraging activity in MTAP‑deleted pancreatic ductal adenocarcinoma. The company is moving toward a pivotal study next year focused on second‑line MTAP‑deleted PDAC based on observed objective responses and progression‑free survival that compared favorably to chemotherapy benchmarks. The readout prompted a $225 million financing to advance clinical development. Analysts note the crowded PRMT5 landscape—players such as BMS and Amgen are developing competing inhibitors—so Tango’s trial design and biomarker strategy will be critical to define differentiation.